Apr 16 2010
Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006. A presentation of the press conference is available on Celsion's website at www.celsion.com/events.cfm.
In addition to Dr. Poon's discussion, he addressed questions from an audience of nearly 30 television, radio, and newspaper media, in both Chinese and English. "Our patients at the University of Hong Kong tolerated the treatment very well, and more importantly, three patients survived for more than three years after ThermoDox treatment, including one who is still in remission," said Dr. Ronnie T.P. Poon.
"The fact that some of these patients were refractory and had prior treatment makes these results even more impressive," remarked Michael H. Tardugno, President & Chief Executive Officer of Celsion Corporation. "The addressable population could be even larger than we imagined before, considering the patient in remission had earlier treatments that were unsuccessful. Additionally, Professor Poon's report that of the 28 treated tumors, 87.5% demonstrated a complete ablation rate at 28 days, suggests improvement in RFA's efficacy to successfully treat local lesions."
SOURCE Celsion Corporation